NCT04616196View on ClinicalTrials.gov

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Head and Neck Squamous Cell CarcinomaColorectal Cancer
Interventions
DRUG

NKTR-255

NKTR-255 IV every 21 days

DRUG

Cetuximab

Cetuximab will be given at specified doses on specified days

Trial Locations (6)

55455

University of Minnesota, Minneapolis

75230

Mary Crowley Cancer Research, Dallas

77030

MD Anderson Cancer Center, Houston

78229

START Center for Cancer Care, San Antonio

92103

University of California, San Diego, San Diego

94158

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
lead

Nektar Therapeutics

INDUSTRY

NCT04616196 - Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | Biotech Hunter | Biotech Hunter